<sup>18</sup>F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study.

Eur J Nucl Med Mol Imaging · 2021 · PMC8263539 · PMID 33909086

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

An interim analysis performed after accrual of 60 patients with 46 evaluable (median follow-up = 13 months) showed a greater than expected, statistically highly significant difference in PFS between the iFLT-PET/CT-positive and iFDG-PET/CT-positive patients (47% difference, 9% PFS for iFLT vs. 56% PFS for iFDG) with negligible difference in NPV between iFDG-PET/CT and iFLT-PET/CT (1% difference, 94% for iFLT vs. 95% for iFDG).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.